Skip to main content
BioPlus Co., Ltd logo

BioPlus Co., Ltd — Investor Relations & Filings

Ticker · 099430 ISIN · KR7099430001 KO Manufacturing
Open in API
Filings indexed 226 across all filing types
Latest filing 2024-03-12 Proxy Solicitation & In…
Country KR South Korea
Listing KO 099430

About BioPlus Co., Ltd

https://ubioplus.com/

BioPlus Co., Ltd. is a company that researches, develops, and manufactures biomaterials, with a primary focus on hyaluronic acid (HA) applications. The company's core competency is its proprietary MDM® Technology, which is used to create a diverse product portfolio for the beauty and healthcare industries. Key products include a range of dermal and body fillers, skin boosters, anti-adhesion agents, biomaterial breast implants, and artificial cartilage. The company aims to provide bio-therapy solutions by addressing fundamental cellular-level issues through its advanced technologies.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for BioPlus Co., Ltd. It details the date, time, location, and agenda items (such as financial statement approval and director remuneration) for the 21st Annual General Meeting. It also includes management reports and governance information as required by law for such notices. This document is a standard proxy solicitation and meeting notice provided to shareholders.
2024-03-12 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Bioplus. It outlines the date, location, and agenda items (financial statements, dividend approval, and director compensation limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming votes, which falls under the Proxy Solicitation & Information Statement category.
2024-02-29 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with other companies' meetings, citing audit schedules and reporting obligations. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2024-02-29 Korean
[기재정정]현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory filing from Bioplus regarding a 'Cash/In-kind Dividend Decision' (현금ㆍ현물배당 결정). It details the dividend amount per share, the total dividend amount, the record date, and the approval process via the upcoming Annual General Meeting. Since the primary purpose of the document is to announce the dividend amount and payment details to shareholders, it falls under the 'Notice of Dividend Amount' category.
2024-02-29 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from the company 'Bioplus' regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the approval process. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2024-02-13 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as an amendment ('정정신고') to a previous filing. It details changes to stock option grants, including adjustments for bonus issues and changes in the number of recipients. This type of disclosure regarding stock-based compensation and capital structure changes falls under the category of regulatory filings that do not fit into more specific categories like 'Director's Dealing' or 'Remuneration Information' (which typically refers to executive compensation reports). Therefore, it is classified as a general regulatory filing.
2024-02-13 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.